A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient
Open-Label Randomised Controlled Trial of Efepoetin Alfa for Treatment of Anaemia Associated With Chronic Kidney Disease Patients Not on Dialysis (ND-CKD). A Non- Inferiority Trial Compared to Methoxy Polyethylene Glycol-Epoetin Beta (MIRCERA)
Sponsor: Novotech (Australia) Pty Limited
Listed as NCT04155125, this PHASE3 trial focuses on Anaemia Associated With Chronic Kidney Disease and remains completed. Sponsored by Novotech (Australia) Pty Limited, it has been updated 11 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2024 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 6 earlier versions
-
Sep 2022 — Jan 2024 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Sep 2022 [monthly]
Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Oct 2020 — Dec 2020 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Apr 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE3
-
Dec 2019 — Apr 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Novotech (Australia) Pty Limited
- PT Kalbe Genexine Biologics
For direct contact, visit the study record on ClinicalTrials.gov .